While several common biomarkers are associated with lung cancer, including EGFR, ALK, KRAS, ROS1, HER2, and others (Villalobos and Wistuba, 2017), the high expression of DLL3 in SCLC has emerged as a promising new target for therapeutic intervention (Sharma et al., 2017). This evidence concerns the gene DLL3 and lung carcinoma.